PerkinElmer said this week that it has completed its acquisition of Caliper Life Sciences for around $600 million.
The agreement, which was announced in September, will, among other things, allow PerkinElmer to combine its expertise in informatics with Caliper's automation and sample-prep technology to bolster PerkinElmer's presence in the next-generation sequencing space (IS 9/13/2011).
In a statement, PerkinElmer CEO Robert Friel said that the deal will "strengthen PerkinElmer's position in personalized medicine."
As part of the deal, Caliper CEO Kevin Hrusovsky will join PerkinElmer as president of life sciences and technology to lead a newly created $500 million business that integrates Caliper with PerkinElmer's research business. Hrusovsky said the business will give "customers the tools and insights" to "understand the origins of disease, create new therapies, and transform personalized medicine."